EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitVergleichsstudie

Oncological Outcomes After Margin‐Negative ( R0 ) Resection in Borderline Resectable Pancreatic Adenocarcinoma: Upfront Surgery Versus Neoadjuvant Treatment—A Contemporary Review

Nan-Ak Wiboonkhwan iD

ANZ Journal of Surgery · 2026-06 · 96 (6) · 1459-1470

DOI: 10.1111/ans.70575 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ANZ Journal of Surgery, online erschienen am 09.03.2026. Verfasst von Nan-Ak Wiboonkhwan. Beteiligte Einrichtung: Department of Surgery, Songklanagarind Vejchavivat Hospital, Hat Yai, Songkhla, Thailand. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neoadjuvant Therapy, Margins of Excision, Pancreatectomy. Die Arbeit nennt 82 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Achieving a margin‐negative (R0) resection in borderline resectable pancreatic cancer (BRPC) is a critical prognostic determinant. The optimal clinical strategy—neoadjuvant therapy (NAT) versus upfront surgery (UFS)—remains a key clinical question.

Methods

This narrative review synthesized contemporary evidence from studies published between 2009 and 2025, encompassing a total of 5598 patients with BRPC. The analysis compared oncological outcomes between NAT and UFS, specifically focusing on resection rates, R0 resection frequency, and median overall survival (OS). Mixed‐cohort studies lacking BRPC subgroup analysis were excluded.

Results

Evidence from both comparative and single‐arm studies indicated that the majority of cohorts achieved significantly higher R0 resection rates and improved median OS following NAT. Resection rates after NAT ranged from 29% to 90%, whereas UFS cohorts reported rates between 62% and 92%. Although resection was more frequent in UFS groups, NAT cohorts demonstrated superior oncological margins; R0 rates in NAT groups ranged from 23% to 100% compared to 14% to 90% in UFS groups. This translated into a survival benefit, with NAT groups achieving a median OS of 11.0 to 43.9 months versus 11.6 to 27.8 months for UFS. NAT also facilitated superior pathological downstaging and reduced lymph node positivity.

Conclusion

Neoadjuvant therapy, utilizing potent multi‐agent regimens, significantly improves R0 resection rates and overall survival in BRPC and is increasingly recognized as the preferred clinical strategy. Currently, this survival benefit is not clearly established for patients with upfront resectable disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsNeoadjuvant TherapyMargins of ExcisionPancreatectomyAdenocarcinomaHumansTreatment OutcomeSurvival Rate

Stichwörter der Autor:innen

R0 resectionborderline resectableneoadjuvant therapyoverall survivalpancreatic ductal adenocarcinomaupfront surgery

Autor:innen und Institutionen

  • Department of Surgery, Songklanagarind Vejchavivat Hospital, Hat Yai, Songkhla, Thailand.

ORCID-Profile: Nan-Ak Wiboonkhwan

Zitieren

APA

Wiboonkhwan, N. A. (2026). Oncological Outcomes After Margin‐Negative ( R0 ) Resection in Borderline Resectable Pancreatic Adenocarcinoma: Upfront Surgery Versus Neoadjuvant Treatment—A Contemporary Review. ANZ Journal of Surgery, 96(6), 1459-1470. https://doi.org/10.1111/ans.70575

Vancouver

Wiboonkhwan NA. Oncological Outcomes After Margin‐Negative ( R0 ) Resection in Borderline Resectable Pancreatic Adenocarcinoma: Upfront Surgery Versus Neoadjuvant Treatment—A Contemporary Review. ANZ Journal of Surgery. 2026;96(6):1459-1470. doi:10.1111/ans.70575

BibTeX
@article{Wiboonkhwan2026,
  author = {Wiboonkhwan, Nan-Ak},
  title = {Oncological Outcomes After Margin‐Negative ( R0 ) Resection in Borderline Resectable Pancreatic Adenocarcinoma: Upfront Surgery Versus Neoadjuvant Treatment—A Contemporary Review},
  journal = {ANZ Journal of Surgery},
  year = {2026},
  volume = {96},
  number = {6},
  pages = {1459--1470},
  doi = {10.1111/ans.70575}
}
Kostenlos starten →